Company profile: Angitia Bio
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics focused on discovery and development of innovative treatments, including AGA111, a Phase III drug candidate to enhance spinal fusion; AGA2115, a Phase I novel biologic for Osteogenesis Imperfecta with FDA Orphan Drug and Rare Pediatric Disease designations; and AGA2118, an additional pipeline program.
Products and services
- AGA2115: A Phase I novel biologic developed for Osteogenesis Imperfecta, FDA Orphan Drug and Rare Pediatric Disease-designated, targeting brittle-bone pathology to progress therapeutic options
- AGA111: A Phase III clinical-stage therapeutic engineered to enhance spinal fusion by promoting robust bone formation and postoperative stabilization, aiming to improve fusion rates and recovery
- AGA2118: A pipeline-listed therapeutic candidate with undisclosed development stage or therapeutic area, positioned for future expansion of Angitia’s portfolio pending further characterization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Angitia Bio
Zyga
HQ: United States
Website
- Description: Provider of surgical solutions developing and commercializing medical devices for treating spine problems, including the SImmetry Sacroiliac Joint Fusion System and developing the Glyder Facet Restoration Device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zyga company profile →
Tenex Health
HQ: United States
Website
- Description: Provider of minimally invasive therapies to remove diseased soft tissue and restore musculoskeletal function. Offers the Tenex Health TX System, which uses ultrasonic energy to treat chronic tendon pain by precisely targeting and removing damaged tissue without open surgery, plus MicroTip tools (TX1, TX2, TX-Bone) for percutaneous tenotomy/fasciotomy, deeper tissue, and calcific/bone pathologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tenex Health company profile →
Sonoma Orthopedics
HQ: United States
Website
- Description: Provider of proprietary orthopedic implants for physicians to address problematic fractures, leveraging the WaviBody technology platform to enable quick, minimally invasive surgical solutions for active patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonoma Orthopedics company profile →
Scandius Biomedical
HQ: United States
Website
- Description: Provider of tissue and bone fixation products for the orthopaedic sports medicine market, including the STRATIS ST femoral fixation system that enables surgeons to perform soft tissue anterior cruciate ligament reconstruction arthroscopically, and the TriTis soft tissue tibial fixation device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scandius Biomedical company profile →
QSpine
HQ: United Kingdom
Website
- Description: Provider of medical devices for the spinal market, designing, manufacturing and distributing them, and working closely with surgeons to design solutions for challenges presented by spinal surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QSpine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Angitia Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Angitia Bio
2.2 - Growth funds investing in similar companies to Angitia Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Angitia Bio
4.2 - Public trading comparable groups for Angitia Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →